Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sars-CoV2 infection in pregnant women with multiple sclerosis.
Aprea MG, Schiavetti I, Portaccio E, Ballerini C, Battaglia MA, Bergamaschi R, Brichetto G, Bunul SD, Calabrese M, Capobianco M, Cavalla P, Celani MG, Clerico M, Cocco E, Comi G, Confalonieri P, Conte A, Cordioli C, De Luca G, De Rossi N, Filippi M, Gumes H, Immovilli P, Inglese M, Karabudak R, Landi D, Lanzillo R, L'Episcopo MR, Lorefice L, Mantero V, Marangoni S, Marfia GA, Masciulli C, Milano E, Moiola L, Orlandi R, Patti F, Perini P, Pesci I, Pucci E, Puthenparampil M, Radaelli M, Salvetti M, Sartori A, Scandellari C, Sen S, Siva A, Strumia S, Teatini F, Tedeschi G, Trojano M, Tutuncu M, Vaula G, Sormani MP, Amato MP; Musc-19 Study Group. Aprea MG, et al. Among authors: lanzillo r. Mult Scler. 2023 Aug;29(9):1090-1098. doi: 10.1177/13524585231176174. Epub 2023 May 26. Mult Scler. 2023. PMID: 37232279 Free PMC article.
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V. Lanzillo R, et al. Mult Scler. 2010 Apr;16(4):450-4. doi: 10.1177/1352458509358909. Epub 2010 Feb 11. Mult Scler. 2010. PMID: 20150398 Clinical Trial.
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M; Italian MS Study Group. Ghezzi A, et al. Mult Scler. 2013 Jul;19(8):1106-12. doi: 10.1177/1352458512471878. Epub 2013 Feb 11. Mult Scler. 2013. PMID: 23401129
Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.
Lavorgna L, Bonavita S, Ippolito D, Lanzillo R, Salemi G, Patti F, Valentino P, Coniglio G, Buccafusca M, Paolicelli D, d'Ambrosio A, Bresciamorra V, Savettieri G, Zappia M, Alfano B, Gallo A, Simone I, Tedeschi G. Lavorgna L, et al. Among authors: lanzillo r. Mult Scler. 2014 Feb;20(2):220-6. doi: 10.1177/1352458513494958. Epub 2013 Jul 9. Mult Scler. 2014. PMID: 23838177
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L. Clerico M, et al. Among authors: lanzillo r. JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200. JAMA Neurol. 2014. PMID: 24977406 Clinical Trial.
Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients.
Patti F, De Stefano M, Lavorgna L, Messina S, Chisari CG, Ippolito D, Lanzillo R, Vacchiano V, Realmuto S, Valentino P, Coniglio G, Buccafusca M, Paolicelli D, D'Ambrosio A, Montella P, Brescia Morra V, Savettieri G, Alfano B, Gallo A, Simone I, Viterbo R, Zappia M, Bonavita S, Tedeschi G. Patti F, et al. Among authors: lanzillo r. PLoS One. 2015 Mar 27;10(3):e0120754. doi: 10.1371/journal.pone.0120754. eCollection 2015. PLoS One. 2015. PMID: 25816303 Free PMC article.
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression.
Moccia M, Lanzillo R, Palladino R, Chang KC, Costabile T, Russo C, De Rosa A, Carotenuto A, Saccà F, Maniscalco GT, Brescia Morra V. Moccia M, et al. Among authors: lanzillo r. Mult Scler. 2016 Apr;22(5):659-67. doi: 10.1177/1352458515599075. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362896
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group. Lanzillo R, et al. Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14. Mult Scler. 2016. PMID: 26466947 Clinical Trial.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Paolicelli D, Cocco E, Di Lecce V, Direnzo V, Moiola L, Lanzillo R, Perini P, Malucchi S, Borriello G, Portaccio E, Panetta V, Fenu G, Sangalli F, Cacciaguerra L, Trojano M; TRACER Group. Paolicelli D, et al. Among authors: lanzillo r. Expert Opin Drug Deliv. 2016 Jun;13(6):799-805. doi: 10.1517/17425247.2016.1158161. Epub 2016 Mar 12. Expert Opin Drug Deliv. 2016. PMID: 26922837
248 results